Rockport Venture Partners - Team
Mark Bosland, Managing Director | Institutional Capital | United States
Mark Bosland is the Founder and Managing Director of Rockport Venture Partners(RVP), he specializes in healthcare & life science companies. Mark founded Rockport Venture Partners in 2001 after spending twelve years working on Wall St. as a European Institutional Salesperson, focused on raising capital for both private and public companies. As a Managing Director at RVP, has represented and closed over 45 transaction in the medical device, diagnostic, biotech and pharma industries, raising over $500M for those companies.
Mark also was a founder and General Partner at Rockport Venture Fund from 2005-2014 a venture capital fund focused exclusively on investing within the life science industry. Previous to RVP, Mark was a Director of Quan Ventures a Swiss based technology crossover venture fund.
Mark holds a Bachelor of Science in Economics from Rutgers University and is a steadfast Scarlet Knight fan.
Beat Merz, Ph.D | Managing Director | Institutional Capital | Europe
Dr. Merz joined Rockport in 2013 as Managing Director of Rockport Venture Securities and Head of European Equity. Dr. Merz brings 16 years of experience in venture and growth stage equity financing and operations to Rockport, including management and leadership of over $150 million in equity financing. Prior to joining Rockport, Dr. Merz was a Partner with Ares Life Sciences. Previously, he was responsible for venture and private equity investment management as Investment Adviser of HBM Partners. Prior to joining HBM Partners, he was Managing Director of NMT New Medical Technologies, where he provided capital, professional advisory services and start-up support for early-stage medical device companies. During his career he has directed investments in the US, Europe and Israel-domiciled companies as well as Board supervision for many of them. He currently serves or has served on the Board of Directors of Micrus Endovascular (acquired by JNJ), Thommen Medical (acquired by private investors), Asthmatx (acquired by BSX), Precimed (acquired by Greatbach), Devax (acquired by BioSensors), BioControl Medical, South Eastern Technologies. Dr. Merz holds a Ph.D. in bio mechanics from ETH Zurich/Switzerland and an MBA from the University of Strathclyde, Glasgow/UK.
Michael Knesevitch, PMP | Managing Director | Deal Orgination & Project Management
Mr Knesevitch joined Rockport in 2014, he brings an environmental science focus to the company. Mike started his career on Wall Street as a self-funded - and self-educated - futures and options market-maker before launching a number of start-up electronic exchanges in the US and Europe including; Euro ECN, TradeSports, Intrade, and the Longitude Trading Platform. At Rockport, Mike focuses on Deal Origination, Diligence, Financial Modeling and Engagement Process Management. He is a graduate of the University of Pennsylvania with a degree in Chemical Engineering and holds the Project Management Professional (PMP) designation from the Project management Institute.
Jake Hindelong Managing Director Institutional Capital – Healthcare
Jake Hindelong joined Rockport in 2016 as a Managing Director. He specializes in healthcare, with a focus on healthcare IT. He brings a research perspective to the team. As an equity research analyst at Credit Suisse and Imperial Capital he published detailed technology and healthcare industry analyses. He worked closely with institutional investors on detailed company-specific due diligence.
For the two years prior to joining Rockport, he worked exclusively on introducing venture-backed and small-cap companies to new investors. Jake holds an MBA from the NYU Stern School of Business and a BS in management from Boston College.
Arthur A. Alfaro
Arthur Alfaro has spent 30 years in the medical device industry with Ethicon, Johnson & Johnson and Boston Scientific.
Mr. Alfaro later joined Sofamor Danek as Division President, which was acquired by Medtronic for $3.6 billion in 1998. After the acquisition Arthur was named President and Director of Osteotech, Inc., which was also acquired by Medtronic in 2010.
In 2008 Arthur founded Nextremity Solutions, a medical device company that offers novel approaches to forefoot surgical intervention where he served as President and CEO.
Currently Arthur serves on the boards of Tyber Medical and Sprains & Strains, Orthopedic Urgent Care Clinics.
Mr. Alfaro earned a BA from the University of Maryland and an MBA from Fairleigh Dickinson University.
Jose Bolanos, MD | Medical Advisor | Market Intelligence
Dr. Bolanos is the Managing Director of Venture-Med, an angel investment and advisory group in Silicon Valley. His focus in on healthcare innovation, healthcare IT, digital health and diagnostic bio-pharma. Dr. Bolanos has served on the advisory boards of many healthcare start-up companies. He is also the CEO for Nimbus-T inc, a healthcare IT company with a novel patent pending patient identity security token. His interests include reducing fraud prevention and securing patient information. He is a Stanford Medical Alumnus with more than 25 years of clinical practice and provides Rockport with strategic market intelligence.
Paul Kelly has been actively involved in the biotechnology industry for more than twenty years as an analyst, consultant and investor. He began his career as an equity analyst at Mabon Securities in 1993, then with UBS Securities, Volpe Brown & Whalen, ING Securities, and Merrill Lynch.
Paul has been named to Fortune magazine’s “All Star Analyst” team in 2000 and currently provides advisory services for public and private biotechnology companies. He actively manages personal investments in the biotechnology industry.
Paul is a magna cum laude graduate from Brown University with a degree in Biotechnology from which he graduated Sigma Xi and Phi Beta Kappa. He attended the University of Rochester School of Medicine and received his MBA in Finance from the William E. Simon School at the University of Rochester.
Michael Schuler has been in the medical device industry for more than 40 years including 18 years with Johnson & Johnson where he was awarded the Phillip B. Hoffman Award for outstanding achievement in R&D and the Johnson & Johnson Entrepreneurial Award. Michael is the only J&J employee to receive that distinction.
From 1992 to 1996, Mr. Schuler was a Founder and CEO of Advanced Surgical, Inc., where he helped raise $12,000,000 in a Private Placement and led their eventual IPO.
Mr. Schuler has served as an independent strategic planning adviser with Olympus USA and SurgiNex, Inc. He held senior positions, including President of the Surgical Products Division at Imagyn Medical Technologies, a NASDAQ listed company, from 1996 to 2000.
Michael currently serves as the Vice-President of New Business Development for The Musculoskeletal Transplant Foundation and is a partner of LumenR, an early stage medical device company that has developed an intra-luminal system for performing therapeutic procedures through natural orifices.
Mr. Schuler was a professor at the Rutgers University Graduate School from 1978-1993. He earned a Bachelors of Science in Industrial Engineering, an MBA and a Masters of Science in Engineering all from Rutgers University. Mr. Schuler still is closely involved with Rutgers serving on a number of industry advisory boards. He holds numerous US international patents.